Bioforce Nanosciences Holdings Stock Performance
| BFNH Stock | USD 0.75 0.08 11.94% |
On a scale of 0 to 100, BioForce Nanosciences holds a performance score of 3. The firm shows a Beta (market volatility) of 4.28, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, BioForce Nanosciences will likely underperform. Please check BioForce Nanosciences' sortino ratio and the relationship between the potential upside and day median price , to make a quick decision on whether BioForce Nanosciences' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in BioForce Nanosciences Holdings are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite fairly fragile basic indicators, BioForce Nanosciences demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 39.9 K |
BioForce |
BioForce Nanosciences Relative Risk vs. Return Landscape
If you would invest 95.00 in BioForce Nanosciences Holdings on October 5, 2024 and sell it today you would lose (20.00) from holding BioForce Nanosciences Holdings or give up 21.05% of portfolio value over 90 days. BioForce Nanosciences Holdings is currently generating 0.6354% in daily expected returns and assumes 15.7028% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioForce, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioForce Nanosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioForce Nanosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as BioForce Nanosciences Holdings, and traders can use it to determine the average amount a BioForce Nanosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0405
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BFNH | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 15.7 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.64 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.04 actual daily | 3 97% of assets perform better |
Based on monthly moving average BioForce Nanosciences is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioForce Nanosciences by adding it to a well-diversified portfolio.
BioForce Nanosciences Fundamentals Growth
BioForce Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of BioForce Nanosciences, and BioForce Nanosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioForce Pink Sheet performance.
| Return On Asset | -21.84 | |||
| Current Valuation | 50.2 M | |||
| Shares Outstanding | 29.27 M | |||
| Price To Earning | (1.52) X | |||
| Price To Book | 866.24 X | |||
| Price To Sales | 3,841 X | |||
| EBITDA | (501.95 K) | |||
| Cash And Equivalents | 9.23 K | |||
| Total Debt | 156.87 K | |||
| Debt To Equity | 4.61 % | |||
| Book Value Per Share | (0.04) X | |||
| Cash Flow From Operations | (77.77 K) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 11.14 K | |||
| Retained Earnings | (21 K) | |||
| Current Asset | 15 K | |||
| Current Liabilities | 1 K | |||
About BioForce Nanosciences Performance
By evaluating BioForce Nanosciences' fundamental ratios, stakeholders can gain valuable insights into BioForce Nanosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioForce Nanosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioForce Nanosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. It sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, and mass merchandisers under the BioForce Eclipse brand, as well as through online and telemarketing. BIOFORCE NANOSCIENCES operates under Packaged Foods classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about BioForce Nanosciences performance evaluation
Checking the ongoing alerts about BioForce Nanosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for BioForce Nanosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioForce Nanosciences is way too risky over 90 days horizon | |
| BioForce Nanosciences has some characteristics of a very speculative penny stock | |
| BioForce Nanosciences appears to be risky and price may revert if volatility continues | |
| BioForce Nanosciences Holdings currently holds 156.87 K in liabilities with Debt to Equity (D/E) ratio of 4.61, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioForce Nanosciences has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioForce Nanosciences until it has trouble settling it off, either with new capital or with free cash flow. So, BioForce Nanosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioForce Nanosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioForce to invest in growth at high rates of return. When we think about BioForce Nanosciences' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (501.95 K) with profit before overhead, payroll, taxes, and interest of 4.36 K. | |
| BioForce Nanosciences Holdings currently holds about 9.23 K in cash with (77.77 K) of positive cash flow from operations. | |
| Roughly 82.0% of BioForce Nanosciences shares are held by company insiders |
- Analyzing BioForce Nanosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioForce Nanosciences' stock is overvalued or undervalued compared to its peers.
- Examining BioForce Nanosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioForce Nanosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioForce Nanosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioForce Nanosciences' pink sheet. These opinions can provide insight into BioForce Nanosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioForce Pink Sheet analysis
When running BioForce Nanosciences' price analysis, check to measure BioForce Nanosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioForce Nanosciences is operating at the current time. Most of BioForce Nanosciences' value examination focuses on studying past and present price action to predict the probability of BioForce Nanosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioForce Nanosciences' price. Additionally, you may evaluate how the addition of BioForce Nanosciences to your portfolios can decrease your overall portfolio volatility.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |